Trials / Not Yet Recruiting
Not Yet RecruitingNCT06828289
Rivastigmine Mini-Tablet for Alzheimer's Disease
Observational Study of Rivastigmine Mini-Tablet in Patients with Alzheimer's Disease
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).
Detailed description
Rivastigmine has received approval for the treatment of Alzheimer's disease. The rivastigmine mini-tablet represents an innovative drug formulation designed to address swallowing difficulties by reducing the size of the dosage form, while also minimizing gastrointestinal side effects through an optimized drug release mechanism. This multi-center, observational study aims to evaluate the effectiveness, safety, and patient compliance associated with rivastigmine mini-tablets in individuals diagnosed with Alzheimer's disease. Assessments will be conducted at the 3rd, 6th, and 12th months of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine Mini-Tablet | Treatment group: Rivastigmine Mini-Tablet |
| DRUG | Donepezil Hydrochloride | Control group: Donepezil Hydrochloride |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-02-14
- Last updated
- 2025-02-20
Source: ClinicalTrials.gov record NCT06828289. Inclusion in this directory is not an endorsement.